Can-Fite BioPharma Ltd. (CANF)
AMEX: CANF
· Real-Time Price · USD
0.66
-0.01 (-1.79%)
At close: Aug 15, 2025, 3:59 PM
0.65
-1.62%
After-hours: Aug 15, 2025, 07:19 PM EDT
Can-Fite BioPharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 179K | 179K | 158K | 158K | 155K | 196K | 196K | 196K | 197K | 204K | 204K | 205K | 204K | 251K | 250K | 148K |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 179K | 179K | 158K | 158K | 155K | 196K | 196K | 196K | 197K | 204K | 204K | 205K | 204K | 251K | 250K | 148K |
Operating Income | -2.02M | -2.02M | -2.05M | -2.05M | -1.83M | -1.86M | -1.78M | -2.71M | -3.08M | -2.57M | -2.07M | -2.37M | -4.03M | -3.51M | -3.13M | -2.17M |
Interest Income | n/a | n/a | n/a | n/a | 127K | 106K | 111K | 162K | 363K | 44K | n/a | n/a | n/a | 110K | n/a | 293K |
Pretax Income | -1.96M | -1.96M | -1.98M | -1.98M | -1.65M | -1.76M | -1.67M | -2.55M | -3.02M | -2.53M | -2.19M | -2.43M | -4.12M | -3.4M | -3.22M | -1.88M |
Net Income | -1.96M | -1.96M | -1.98M | -1.98M | -1.65M | -1.76M | -1.67M | -2.39M | -2.96M | -2.44M | -2.43M | -2.56M | -4.12M | -3.4M | -3.22M | -1.88M |
Selling & General & Admin | 761K | 761K | 762.5K | 762.5K | 722K | 762K | 624K | 847K | 826K | 741K | 822K | 754K | 1.13M | 822K | 876K | 1.02M |
Research & Development | 1.44M | 1.44M | 1.44M | 1.44M | 1.27M | 1.3M | 1.36M | 2.06M | 2.45M | 2.04M | 1.45M | 1.82M | 3.1M | 2.94M | 2.51M | 1.3M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 2.2M | 2.2M | 2.21M | 2.21M | 1.99M | 2.06M | 1.98M | 2.91M | 3.28M | 2.78M | 2.27M | 2.58M | 4.23M | 3.76M | 3.38M | 2.32M |
Interest Expense | n/a | n/a | n/a | n/a | 14K | 3K | n/a | n/a | 16K | 44K | n/a | n/a | n/a | 110K | n/a | 293K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 2.2M | 2.2M | 2.21M | 2.21M | 1.99M | 2.06M | 1.98M | 2.91M | 3.28M | 2.78M | 2.27M | 2.58M | 4.23M | 3.76M | 3.38M | 2.32M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | -3.5K | -4K | -162K | -64K | -88K | 242K | 128K | n/a | -3K | -4K | -3K |
Shares Outstanding (Basic) | 8.44M | 8.44M | 6.07M | 6.07M | 4.95M | 4.08M | 4.09M | 3.93M | 2.72M | 2.72M | 2.72M | 2.72M | 1.36M | 1.83M | 1.72M | 1.61M |
Shares Outstanding (Diluted) | 8.44M | 8.44M | 6.07M | 6.07M | 4.95M | 4.08M | 4.08M | 3.93M | 2.72M | 2.72M | 2.72M | 2.72M | 2.22M | 1.83M | 1.72M | 1.61M |
EPS (Basic) | -0.24 | -0.24 | -0.33 | -0.33 | -0.33 | -0.42 | -0.42 | -0.66 | -1.11 | -0.93 | -0.81 | -0.9 | -3.03 | -1.86 | -1.86 | -1.17 |
EPS (Diluted) | -0.24 | -0.24 | -0.33 | -0.33 | -0.33 | -0.42 | -0.42 | -0.66 | -1.11 | -0.93 | -0.81 | -0.9 | -3.03 | -1.86 | -1.86 | -1.17 |
EBITDA | -2.02M | -2.02M | -2.05M | -2.05M | -1.83M | -1.86M | -1.78M | -2.71M | -3.08M | -2.57M | -2.07M | -2.37M | -4.02M | -3.51M | -3.13M | -2.17M |
EBIT | -2.02M | -2.02M | -2.05M | -2.05M | -1.83M | -1.86M | -1.78M | -2.71M | -3.08M | -2.57M | -2.07M | -2.37M | -4.03M | -3.51M | -3.13M | -2.17M |
Depreciation & Amortization | 3K | 3K | 500.00 | 500.00 | 3.75K | 3.5K | 4K | 3.5K | 3.5K | 3.5K | 3K | 3.5K | 3.5K | 3K | 4K | 3K |